David W. Jenkins
Chief Scientific OfficerDr. David W. Jenkins, M.A., Ph.D., is Chief Scientific Officer of BioCryst Pharmaceuticals, Inc. from July 15, 2026. Dr. Jenkins has many years working in the biopharmaceutical industry and has broad experience leading R&D and external innovation programs across a range of therapeutic areas, development stages and modalities. He served as Senior Vice President, Head of Research & External Innovation at Ipsen, helping to oversee the preclinical drug discovery portfolio across oncology, rare disease and neuroscience. Under his leadership, Ipsen added more than 35 assets to its pipeline across therapeutic areas and stages. Previously, Dr. Jenkins held scientific leadership roles at TESARO, MedImmune, Novartis and AstraZeneca. He holds a PhD in Molecular Pharmacology and Neuroscience and an MA in Pharmacology from the University of Cambridge, U.K.
Positions
- Company NameBioCryst Pharmaceuticals, Inc.Stock CodeBCRXPositionChief Scientific OfficerColleagues
- CKCharles K. GayerCEO, President & Director
- VJVincent J. MilanoIndependent Chairman
- BGBabar GhiasCFO & Head of Corporate Development
- APAlane P. BarnesSenior VP, Chief Legal Officer & Corporate Secretary
- JRJohn RueschChief Technical Operations Officer
- AGAlan G. LevinIndependent Director
- SKSteven K. GalsonIndependent Director
- AMA. Machelle SandersIndependent Director
